GTB-3650 TriKE® Phase 1 trial has successfully completed Cohort 1 and Cohort 2 dosing, treating a total of four patients; following Cohort 2's formal safety review, it has advanced into Cohort 3 and ...

Results from the Phase II COLLECTiVE202 trial (NCT05370885) demonstrated a statistically significant difference between VE202 ...

In this Q&A, Rohit Nambisan, CEO of Lokavant, and Jonathan Crowther, head of predictive analytics, Pfizer, explore how AI is ...

Inhibikase Therapeutics, Inc. ( ($IKT) ) has released its Q2 earnings. Here is a breakdown of the information Inhibikase Therapeutics, Inc.

Net loss (GAAP) narrowed to $6.1 million in Q2 2025, a 22.8% improvement from the prior-year period, driven by reduced research and development spending. No product revenue reported; The company’s ...

Key Points GAAP loss per share of $(0.47) for Q2 2025 was narrower than the $(0.53) analysts had expected, despite an ongoing absence of revenue. Research and development expenses (GAAP) increased 35.

Q2 2025 Management View Chaim Lebovits, President and CEO, reaffirmed that "our top priority is advancing NurOwn into our ...

Management reiterated the expectation that Elfabrio royalties will exceed $100 million by 2030, based on a projected 15% to 20% market share of the Fabry disease market.

Over the past 20 years, a class of cancer drugs called CD40 agonist antibodies have shown great promise-and induced great disappointment.

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target ...

Operator: Greetings. Welcome to PDS Biotech Second Quarter 2025 Earnings Conference Call. [Operator Instructions] As a ...

Therapeutic advances have altered the neurodegenerative trajectory and improved clinical outcomes for individuals with spinal muscular atrophy. Current therapies increase concentrations of survival ...